Présentation de l'entreprise
Delcath Systems, Inc. operates as an interventional oncology company dedicated to the treatment of primary and metastatic liver cancers within the United States and European markets. The firm specializes in the development and commercialization of therapeutic products, with its lead product candidate being the HEPZATO KIT, a melphalan for injection coupled with a hepatic delivery system designed to administer high-dose chemotherapy. This entity functions within the Healthcare sector, specifically the Medical Devices industry, a classification that defines its business model around the creation of specialized equipment and consumables for clinical procedures. The company currently maintains a market capitalization of $342.25 million and reports annual revenue of $85.23 million, supported by a workforce of 156 employees. These valuation and revenue figures indicate that Delcath Systems holds a mid-sized position in the specialized medical device landscape, reflecting a balance between established operational scale and the growth potential inherent in emerging oncology technologies.
Santé financière
The company generated revenue of $85.23 million over the trailing twelve months, resulting in a net income of $2.70 million and an EBITDA of $898,000. The significant disparity between the revenue figure and the net income reveals a cost structure where operating expenses, likely driven by research, development, and sales efforts, consume a substantial portion of top-line growth before reaching the bottom line. Despite the modest net income, the company demonstrates robust financial flexibility through a free cash flow of $20.29 million, which suggests strong cash generation capabilities relative to its current earnings. This level of free cash flow provides the necessary liquidity to fund ongoing R&D initiatives and capital expenditures without relying heavily on external financing. Analysis of the three primary margins shows a gross margin of 86.2%, indicating high pricing power or low cost of goods sold typical of proprietary medical technologies, contrasted with an operating margin of -10.5% and a profit margin of 3.2%. The negative operating margin highlights that while the core product is profitable to manufacture, high overhead costs are currently eroding operating efficiency before the final profit calculation. On the liability side, the company holds $91.04 million in cash against $936,000 in debt, resulting in a debt-to-equity ratio of 0.84. This balance sheet structure is conservative, as the cash reserves significantly exceed total debt obligations, minimizing financial risk. Furthermore, a current ratio of 10.92 underscores exceptional short-term liquidity, implying the firm can easily meet its current liabilities with its available current assets. Finally, the return on equity stands at 3.0% while the return on assets is 0.4%, metrics that reveal management is currently leveraging the capital base to generate modest returns, a common characteristic for growth-stage companies prioritizing reinvestment over immediate shareholder yield.
Évaluation de la valorisation
The valuation metrics present a complex picture, with a trailing P/E ratio of 140.71 compared to a forward P/E of -50.26. The divergence between these two figures implies that the market is pricing in a significant deterioration of future earnings, as the negative forward P/E indicates analysts do not expect the company to generate positive earnings in the upcoming period. The price-to-book ratio is recorded at 3.07, which indicates that the market is assigning a premium to the company's assets well above their book value, likely reflecting the intangible value of its intellectual property and pipeline potential. Alternative valuation metrics such as the price-to-sales ratio of 4.02 and an EV/EBITDA of 280.79 suggest that the stock is trading at a significant multiple relative to its sales and earnings power, typical for firms with high growth expectations but currently limited profitability. Price action over the last year has seen the stock fluctuate between a 52-week low of $8.12 and a 52-week high of $18.23. Without the specific current share price, the precise percentage position relative to the trading range cannot be calculated, but the wide spread between the high and low indicates high volatility. The beta value of 0.43 suggests that the stock price exhibits low volatility relative to the broader market, moving less dramatically than the overall index during periods of market fluctuation.
Growth & Income
Delcath Systems reports a revenue growth rate of 37.3% year-over-year, while the earnings growth rate is listed as N/A. The absence of reported earnings growth data, coupled with the current negative forward earnings multiple, implies that earnings are not currently growing at a pace that supports positive valuation expansion, as the company likely still faces challenges in translating revenue growth into proportional net income. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Consequently, the company retains all its earnings to reinvest into growth initiatives such as product development and market expansion rather than distributing cash to shareholders. The overall growth and income profile is characterized by robust top-line expansion driven by a specific oncology product, offset by a lack of current dividend income and profitability challenges that prevent positive earnings growth metrics from materializing at this stage.